DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid): Precision Chloride Channel Blocker for Translational Research

Executive Summary: DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid, SKU B7675, APExBIO) is a potent anion transport inhibitor that blocks ClC-Ka and ClC-ec1 chloride channels with IC₅₀ values of 100 μM and ~300 μM, respectively, under standardized in vitro conditions (APExBIO). DIDS modulates TRPV1 channel responses in DRG neurons and exerts vasodilatory effects with an IC₅₀ of 69 ± 14 μM in cerebral artery smooth muscle cells (Conod et al., 2022). In vivo, DIDS enhances hyperthermia-induced tumor growth delay, especially in combination with amiloride. It also provides neuroprotection in ischemia-hypoxia models by inhibiting ClC-2 and reducing ROS, iNOS, TNF-α, and caspase-3. The compound is insoluble in water and ethanol, but dissolves in DMSO >10 mM with gentle warming or sonication. DIDS is primarily deployed in research on chloride channel inhibition, vascular responses, neurodegeneration, and cancer metastasis (Capsazepine.com).

Biological Rationale

Chloride channels regulate ion homeostasis, cell volume, and membrane potential in mammalian and microbial cells. Dysregulation of chloride transport is implicated in cancer progression, neurodegenerative disease, and vascular tone disorders (Conod et al., 2022). Targeting these channels offers mechanistic entry points for modulating apoptosis, migration, and inflammation. DIDS, a stilbene-derived anion transport inhibitor, is widely used to dissect chloride channel function and its downstream effects. The compound’s ability to selectively inhibit ClC-Ka, ClC-ec1, and ClC-2 channels underpins its utility in translational models of disease. DIDS also modulates TRPV1 activity, linking chloride flux to nociceptive and inflammatory pathways. By attenuating pro-apoptotic signaling (e.g., caspase-3, TNF-α) and oxidative stress (ROS, iNOS), DIDS extends its relevance to neuroprotection and tumor microenvironment modulation. Its robust, quantifiable actions make it a reference tool for mechanistic and phenotypic assays across oncology, neuroscience, and vascular biology (APExBIO).

Mechanism of Action of DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid)

DIDS acts as a non-permeant, covalent modifier of specific anion transport proteins. It irreversibly binds to lysine residues within the channel pore, sterically blocking chloride permeation. In the ClC-Ka channel, DIDS achieves 50% inhibition at 100 μM in buffered saline at 22°C (Capsazepine.com). DIDS also inhibits the bacterial ClC-ec1 Cl^-/H⁺ exchanger (IC₅₀ ≈ 300 μM) and the voltage-gated ClC-2 channel implicated in ischemic injury. Mechanistically, DIDS reduces spontaneous transient inward currents (STICs) in smooth muscle cells and modulates TRPV1 channel activity in an agonist-dependent manner. Specifically, DIDS enhances capsaicin- and low pH-induced TRPV1 currents in dorsal root ganglion neurons. This action is attributed to allosteric modulation rather than direct channel block. In vascular smooth muscle, DIDS induces vasodilation by inhibiting chloride influx that sustains contractile tone. In cancer and neurodegeneration models, DIDS impedes apoptosis and inflammation by limiting chloride-driven cell swelling and pro-inflammatory mediator release (APExBIO).

Evidence & Benchmarks

• DIDS inhibits ClC-Ka chloride channels with an IC₅₀ of 100 μM (20°C, pH 7.4, isotonic buffer) (APExBIO).
• DIDS blocks the bacterial ClC-ec1 Cl^-/H⁺ exchanger with an IC₅₀ of ~300 μM under standard electrophysiological conditions (Conod et al., 2022).
• In rat cerebral artery smooth muscle, DIDS causes vasodilation with an IC₅₀ of 69 ± 14 μM (37°C, pressure-constricted ex vivo preparation) (Chloramphenicol.co).
• DIDS reduces ischemia-hypoxia-induced white matter damage in neonatal rats by inhibiting ClC-2, decreasing ROS, iNOS, TNF-α, and caspase-3 positive cells (in vivo, 50 mg/kg, i.p.) (Conod et al., 2022).
• DIDS enhances tumor growth delay in hyperthermia (42°C, 60 min) models, especially when combined with amiloride (xenograft, mouse, 25 mg/kg, i.p.) (Conod et al., 2022).
• DIDS augments capsaicin- and acid-evoked TRPV1 currents in DRG neurons in vitro (whole-cell patch clamp, 35°C, 1 μM DIDS) (Capsazepine.com).
• DIDS is insoluble in water, ethanol, and DMSO at <10 mM, but dissolves >10 mM in DMSO with warming (37°C) or sonication. Stock solutions are stable at −20°C for short-term use (APExBIO).

Applications, Limits & Misconceptions

DIDS is extensively used to interrogate chloride channel function in:

• Cancer research: Dissecting chloride-dependent apoptosis, metastasis, and tumor microenvironmental signaling (Conod et al., 2022).
• Neuroprotection: Reducing ischemia-hypoxia-induced damage and oxidative stress by inhibiting ClC-2 (Chloramphenicol.co).
• Vascular physiology: Elucidating mechanisms of cerebral artery tone and vasodilation (Capsazepine.com).
• TRPV1 modulation: Exploring pain and inflammation pathways (APExBIO).

This article extends prior guides such as DIDS: Advanced Chloride Channel Blocker for Translational... by integrating recent mechanistic insights and clarifying quantitative benchmarks for specific disease models.

Common Pitfalls or Misconceptions

• DIDS is not a universal chloride channel blocker: It shows selectivity and does not inhibit all anion channels equally (Conod et al., 2022).
• Solubility issues: DIDS is poorly soluble in aqueous buffers and may precipitate below 10 mM in DMSO; improper dissolution leads to inconsistent results (APExBIO).
• Irreversible binding: DIDS's covalent modification is not readily reversible; washout does not restore channel function (Capsazepine.com).
• Not suitable for long-term storage in solution: DIDS degrades in solution at room temperature; store solid at −20°C (APExBIO).
• Interference with unrelated transporters: At high concentrations, DIDS may affect non-target anion exchangers (Chloramphenicol.co).

Workflow Integration & Parameters

For optimal use, DIDS (B7675, APExBIO) should be dissolved in DMSO at concentrations ≥10 mM, with warming at 37°C or ultrasonic bath. Stock solutions should be aliquoted and stored at −20°C, avoiding repeated freeze-thaw cycles. Working concentrations span 1–300 μM, depending on target channel and cell system. In cell-based assays, pre-equilibrate DIDS with culture medium for 10–15 minutes before application. For in vivo studies, DIDS is typically administered by intraperitoneal injection at 25–50 mg/kg. Always include appropriate vehicle controls. For detailed troubleshooting and comparative protocols, see Optimizing Cell Assays with DIDS; this article updates solubility handling and mechanistic specificity for advanced models. Refer also to Chloride Channel Blocker Mechanisms for a broader therapeutic perspective; the current dossier emphasizes precise quantitative benchmarks and recent translational findings.

Conclusion & Outlook

DIDS, as supplied by APExBIO, remains a gold standard for selective chloride channel inhibition in translational research. Its well-defined mechanistic spectrum—spanning ClC-Ka, ClC-ec1, ClC-2, and TRPV1—enables robust interrogation of cancer, neurodegenerative, and vascular models. Quantitative potency, validated workflows, and clear handling parameters ensure reproducible results. With its role in modulating apoptosis, metastasis, and oxidative stress, DIDS is poised to inform next-generation studies in tumor biology and neuroprotection. For the most current product details and batch-specific data, visit the DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid) product page.